In 2009, a study published in Nature changed the trajectory of longevity research. Researchers at three independent laboratories reported that rapamycin — a drug originally developed to prevent organ rejection in transplant patients — extended the maximum lifespan of mice by 9 to 14 percent when treatment began at 600 days of age, the equivalent of approximately 60 human years. The effect was robust across both sexes and across genetically diverse mouse strains. It was the first time a drug had been shown to extend lifespan in a mammal when treatment began in middle age.
The mechanism was mTOR — mechanistic target of rapamycin, a protein kinase that sits at the intersection of nutrient sensing, cellular growth, autophagy, and aging biology. Rapamycin inhibits mTOR, and mTOR inhibition had already been connected to lifespan extension through caloric restriction studies. The 2009 mouse result suggested that the caloric restriction pathway could be pharmacologically activated — that a drug could mimic one of the most reproducible interventions for extending healthy lifespan in laboratory animals.
By 2026, that mouse result has spawned a field, a community of biohackers self-experimenting with off-label prescriptions, a longevity telehealth industry, and — crucially — the first completed randomized controlled trials in healthy humans. What those trials have found is instructive, honest, and considerably more complicated than the enthusiasm surrounding the field would suggest.
Three Distinct Drug Classes, Three Distinct Mechanisms
The longevity drug landscape of 2026 is organized around three mechanistic approaches, each with different biological rationale, different clinical evidence, and different risk profiles.
Rapamycin targets mTOR inhibition — slowing the cellular growth and protein synthesis machinery that, in aging organisms, contributes to cellular dysfunction through overactivation. In yeast, worms, flies, and mice, mTOR inhibition consistently extends lifespan. The biological logic is that aging organisms’ cells continue to grow when they should be recycling damaged components — inhibiting mTOR shifts the balance toward autophagy and cellular maintenance.
Senolytics target senescent cells — the so-called zombie cells that have lost the ability to divide but resist programmed cell death, accumulating in aging tissues and secreting inflammatory signals through what researchers call the senescence-associated secretory phenotype, or SASP. In mice, clearing senescent cells has extended median lifespan, improved physical function, and delayed the onset of multiple age-related conditions. The leading human senolytic combination is dasatinib plus quercetin — D+Q — where dasatinib, an FDA-approved cancer drug, and quercetin, a natural flavonoid found in onions and apples, work synergistically to activate the apoptotic pathways that senescent cells have disabled to survive.
NAD+ precursors — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — target the decline in NAD+ levels that occurs with aging. NAD+ is essential for energy metabolism, DNA repair through sirtuins, and mitochondrial function. NAD+ levels fall by up to 80 percent with increasing age in some tissues. Restoring NAD+ through precursor supplementation has extended lifespan and improved healthspan in animal models. In humans, NR and NMN reliably raise circulating NAD+ levels — a pharmacological effect that is well-established. Whether raising NAD+ levels translates into meaningful health benefits is the question trials are now attempting to answer.
The PEARL Trial: The Most Important Human Data, and the Most Misreported
The Participatory Evaluation of Aging with Rapamycin for Longevity trial — PEARL — is the first completed, long-term, randomized, placebo-controlled trial of rapamycin specifically for longevity purposes in healthy adults. It enrolled 114 participants with an average age of approximately 60, randomized them to placebo, 5 mg weekly rapamycin, or 10 mg weekly rapamycin, and followed them for 48 weeks. The primary endpoint was changes in visceral adiposity measured by DEXA scan — the hypothesis being that rapamycin would reduce the metabolically harmful visceral fat that accumulates with aging.
The primary outcome — visceral adiposity — did not significantly change. The effect size was essentially zero. The primary hypothesis was not supported.
This is the result that most longevity community coverage of PEARL omitted, minimized, or buried beneath secondary findings. It deserves to be stated plainly: the most rigorously conducted human longevity trial of rapamycin failed its primary endpoint.
What PEARL did find on secondary measures is more nuanced. The PEARL trial demonstrated that low-dose intermittent rapamycin was well tolerated over one year and resulted in modest changes in biomarkers of biological aging, though long-term clinical benefits remain to be established. Some participants showed improvements in biological age estimates derived from epigenetic clocks and other molecular markers. But these are biomarker outcomes, not clinical outcomes — they measure proxies of aging rather than the outcomes that matter to patients: disease incidence, functional capacity, quality of life, or longevity itself. The gap between improving a biomarker and improving a clinical outcome is precisely where longevity medicine’s translation problem lives.
The PEARL result does not prove that rapamycin does not work for longevity in humans. It proves that rapamycin at the doses and duration tested did not reduce visceral fat in a 48-week trial of 114 people. The animal data was obtained in mice treated for their entire adult lives; PEARL treated humans for one year starting in their sixties. The negative primary endpoint is sobering and important, but it is not the definitive human test of the mTOR inhibition hypothesis — that test would require much larger samples, longer durations, and harder clinical endpoints.
Senolytics: Strong Animal Data, Early Human Evidence
The senolytic story in humans is earlier-stage but in some respects more specific. Unlike rapamycin, which targets a broadly distributed signaling pathway with pleiotropic effects throughout the body, senolytics have a defined cellular target — senescent cells — and a defined mechanism of action — inducing apoptosis in cells that have disabled their own death pathways.
The human evidence for senolytics has accumulated through disease-specific trials rather than longevity trials in healthy individuals. A Mayo Clinic Phase 1 trial of dasatinib plus quercetin in patients with idiopathic pulmonary fibrosis — a condition linked to senescent cell accumulation in lung tissue — found that the combination improved physical function at six months, with patients walking farther and showing trends toward improved lung function. A separate Mayo Clinic trial in patients with diabetic kidney disease showed that D+Q reduced circulating senescent cell burden and improved physical function markers.
The STAMINA trial — Senolytics to Improve Cognition and Mobility in Older Adults at Risk of Alzheimer’s Disease — is an open-label single-arm trial funded by the National Institute on Aging, led by investigators at Harvard’s Marcus Institute for Aging Research, testing the feasibility of D+Q delivery for preservation of cognitive function among older adults at risk of Alzheimer’s disease. This trial represents the entry of senolytics into neurodegenerative disease research — extending the approach from pulmonary and kidney disease to the central nervous system.
A 2025 pilot trial protocol from Washington University in St. Louis is testing D+Q in older adults with schizophrenia, schizoaffective disorder, and treatment-resistant depression — conditions linked to accelerated biological aging — using two consecutive days of dasatinib plus quercetin at baseline and weeks one through three, with MRI assessment of structural and functional brain health at baseline and 10 weeks.
The honest summary of senolytics in humans as of mid-2026 is: promising disease-specific results in conditions where senescent cell burden is believed to be mechanistically central, no completed randomized controlled trials in healthy individuals for prevention purposes, and real concerns about using a chemotherapy drug — dasatinib carries genuine side effects — in people who are not sick.
NAD+ Precursors: Reliable Pharmacology, Uncertain Clinical Translation
The NAD+ precursor story is the clearest example of the gap between biological mechanism and clinical benefit. The pharmacology is established: oral NR and NMN reliably raise NAD-related biomarkers in humans, while human effects on metabolic, vascular, and performance outcomes are mixed, and longer, powered randomized controlled trials with clinically meaningful endpoints are needed.
A January 2026 randomized trial in 65 healthy adults found that NR and NMN both doubled circulating NAD+ levels over 14 days, while nicotinamide — a cheaper and more widely available NAD+ precursor — did not significantly raise NAD+ and increased homocysteine levels, reflecting increased methylation demand. The trial confirmed that NR and NMN are pharmacologically effective at raising NAD+ in humans and that nicotinamide is not equivalent to either.
What remains unclear is what raising NAD+ actually does for human health over clinically meaningful periods. The animal data — where NAD+ restoration improved metabolism, inflammation, and function in aged rodents — has not translated cleanly to human clinical outcomes. As of early 2026, there is no convincing clinical evidence that NMN extends lifespan or reverses aging in humans, and the latest literature primarily confirms that the translation from animal models to humans remains limited, with larger, longer, and better-designed clinical trials required.
A 2025 Nature Aging review of NAD+ targeting strategies documented emerging applications in Alzheimer’s disease, Parkinson’s disease, and metabolic conditions — where NAD+ depletion is mechanistically linked to disease processes — as more promising near-term clinical targets than healthy aging prevention. This is consistent with the general pattern across longevity drugs: disease-specific applications where the mechanism is directly relevant are closer to clinical validation than prevention applications in healthy individuals.
The Regulatory Question That Defines the Field
Underlying all three drug classes is a regulatory problem that shapes what clinical evidence is possible to generate. The FDA does not recognize aging as a disease. A drug cannot be approved to treat aging — only to treat specific age-related conditions. This means that trials of longevity drugs in healthy individuals, aimed at preventing or delaying the onset of age-related disease, do not have a clear regulatory pathway to approval even if they succeed. Successful clinical evidence of longevity benefit in healthy humans could not translate directly into an approved indication.
The TAME trial — Targeting Aging with Metformin — is the most ambitious attempt to establish clinical evidence in this context. It is testing whether metformin, an inexpensive generic diabetes drug with suggestive longevity signals in observational data, reduces the rate of developing age-related diseases as a composite endpoint in 3,000 older adults over six years. TAME was explicitly designed to create a regulatory pathway for aging as a clinical target — demonstrating that trials of aging itself, rather than specific diseases, can produce meaningful clinical evidence. Its results, expected in the late 2020s, could reshape the regulatory landscape for all longevity drugs.
What the Honest Picture Looks Like
The longevity drug field in 2026 is at an inflection point that is both more advanced than popular coverage suggests and less conclusive than longevity community enthusiasm implies. More advanced because there are now completed randomized controlled trials in humans — not just observational surveys or animal studies — and those trials are providing genuine data that constrains the hypothesis space. Less conclusive because the trials that exist are small, short, and focused on biomarkers rather than clinical outcomes, and the most important trial of rapamycin failed its primary endpoint while showing secondary signals that resist easy interpretation.
The self-experimentation community — thousands of people taking off-label rapamycin, D+Q cycles, or NMN based on the animal data and mechanistic rationale — is generating real-world safety data and self-reported outcomes that complement formal trials. A survey of 333 self-reported rapamycin users found generally mild side effects and high perceived benefit. This is useful for characterizing real-world use but cannot establish causation, and the population of people seeking out longevity interventions differs systematically from the general aging population in ways that make observational inference unreliable.
Why It Matters
The global burden of aging-related disease — cardiovascular disease, cancer, neurodegeneration, metabolic dysfunction, frailty — is the dominant challenge of twenty-first-century medicine in high-income countries. Current medicine treats each of these conditions separately, after they have developed, with limited ability to alter the underlying biology that produced them simultaneously. If any of the longevity drug approaches can be shown to reduce the rate at which aging biology drives disease onset, the public health implications would exceed those of almost any other medical advance. The question is whether the biology is tractable in humans in the way it has proven tractable in mice, and whether the clinical trials of sufficient size, duration, and rigor to answer that question will be funded and completed before the field fragments into premature commercialization of unproven interventions.
Closing Human Dimension
The biology of aging is not destiny. Every decade of basic science has revealed more mechanisms by which cells and tissues deteriorate with age, and increasingly, those mechanisms have proven modifiable in model organisms. The distance between modifiable in a mouse and beneficial in a human has humbled researchers across medicine — but it has also been crossed, repeatedly, when the mechanism is correctly identified and the clinical question correctly framed. The longevity drug field is at the stage where that crossing is being attempted in earnest, with real data accumulating that will either confirm or redirect the biological intuitions that have animated it. The PEARL result is a redirection signal, not a termination signal. The senolytics results are early encouragement, not proof. The NAD+ data is mechanistically solid, clinically unfinished. The field is exactly where a field at this stage of development should be — producing results that are genuinely informative without being definitive.
Sources
1. Hillary Lin MD. “Rapamycin for Longevity: Complete Clinical Guide (2026).” April 2026. https://hillarylinmd.com/guides/rapamycin-longevity — documents PEARL trial design, primary endpoint failure, and secondary findings.
2. medRxiv. “Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results.” NCT04488601. https://www.medrxiv.org/content/10.1101/2024.08.21.24312372.full.pdf
3. PMC / Frontiers in Aging. “Rapamycin for longevity: the pros, the cons, and future perspectives.” June 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/
4. Aging-US. “What is the clinical evidence to support off-label rapamycin therapy in healthy adults?” August 2025. https://www.aging-us.com/article/206300/text
5. PMC. “Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders.” F1000Research (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120425/
6. ClinicalTrials.gov / Harvard Marcus Institute. “STAMINA: Senolytics to Improve Cognition and Mobility in Older Adults at Risk of Alzheimer’s Disease.” NCT05422885. https://cdn.clinicaltrials.gov/large-docs/85/NCT05422885/SAP_001.pdf
7. valbiohacker.com. “Longevity Dispatch: 3 Longevity Breakthroughs That Just Changed What We Know About Aging.” June 2026. https://www.valbiohacker.com/p/newsletter-your-gut-is-aging-your — documents senolytic clinical landscape and PEARL summary.
8. ScienceDirect. “NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review.” February 2026. https://www.sciencedirect.com/science/article/pii/S1568163726000498
9. Every Day Better. “Latest NMN Studies 2026: Longevity & Anti-aging Research.” June 2026. https://everydaybetter.nl/en/latest-nmn-studies-2026-what-do-clinical-trials-really-say-about-longevity-and-anti-aging/
10. Renue By Science. “A Current List of Completed NMN Human Trials.” https://renuebyscience.com/pages/a-current-list-of-completed-nmn-human-trials — documents January 2026 NMN/NR/NAM comparative trial.
Idea originated at artificialideas.org. Article researched and written by Claude Sonnet 4.6. Published at artificialideas.org.
Artificial Ideas 